HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.

AbstractBACKGROUND:
Arteriovenous fistulas are the recommended permanent vascular access (VA) for chronic hemodialysis. However, in the United States most patients begin chronic hemodialysis with a catheter. Recent data suggest that VA type contributes to recombinant human erythropoietin (rHuEPO) resistance. We examined catheter insertions, VA infections, and anemia management in Medicare, rHuEPO-treated, chronic hemodialysis patients.
METHODS:
We compared hemoglobin values and rHuEPO and intravenous iron dosing with concurrent catheter insertions and VA infections in 186,348 period-prevalent patients in 2000. We studied anemia management after catheter insertions and VA infections in 67,410 incident patients from 1997 to 1999. Multiple linear regression models examined follow-up hemoglobin and rHuEPO dose per week (rHuEPO/wk) by numbers of catheter insertions and hospitalizations for VA infection.
RESULTS:
In the prevalent cohort, increasing temporary and permanent catheter insertions and VA infections were associated with slightly lower hemoglobin, higher rHuEPO doses, and higher intravenous iron doses. In the incident cohort, compared to patients with no VA infections or no catheter insertions (temporary or permanent), respectively, patients with 2+ VA infections or 2+ catheter insertions had 0.12 g/dL and 0.06 g/dL lower mean hemoglobin (P = 0.0028 and P < 0.0001), and 25.7% and 12.2% higher mean rHuEPO/wk (P < 0.0001).
CONCLUSION:
Higher rHuEPO doses may be required to maintain similar or slightly lower mean hemoglobin values among chronic hemodialysis patients with higher numbers of catheter insertions and VA infections, compared to patients without any.
AuthorsTricia L Roberts, Gregorio T Obrador, Wendy L St Peter, Brian J G Pereira, Allan J Collins
JournalKidney international (Kidney Int) Vol. 66 Issue 6 Pg. 2429-36 (Dec 2004) ISSN: 0085-2538 [Print] United States
PMID15569336 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
Topics
  • Adolescent
  • Adult
  • Aged
  • Anemia (drug therapy, epidemiology)
  • Arteriovenous Shunt, Surgical (adverse effects, statistics & numerical data)
  • Child
  • Child, Preschool
  • Cohort Studies
  • Erythropoietin (therapeutic use)
  • Female
  • Hemoglobins
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Infections (epidemiology)
  • Kidney Failure, Chronic (epidemiology, therapy)
  • Male
  • Middle Aged
  • Prevalence
  • Recombinant Proteins
  • Renal Dialysis
  • Urinary Catheterization (adverse effects, statistics & numerical data)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: